• Je něco špatně v tomto záznamu ?

Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

G. Battipaglia, M. Labopin, D. Blaise, JL. Diez-Martin, A. Bazarbachi, A. Vitek, P. Chevallier, L. Castagna, G. Grillo, E. Daguindau, J. López-Jiménez, Y. Koc, A. Ruggeri, A. Nagler, M. Mohty

. 2022 ; 28 (9) : 587.e1-587.e7. [pub] 20220614

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22024692

The use of haploidentical hematopoietic cell transplantation (haplo-HCT) with peripheral blood stem cells (PBSCs) to treat acute myelogenous leukemia (AML) is increasing. We explored whether the addition of antithymocyte globulin (ATG) to post-transplantation cyclophosphamide (PTCy) allows better outcomes compared with PTCy alone in haplo-HCT with PBSCs (haplo-PBSCT). We included 441 adult patients undergoing a first haplo-PBSCT for AML in first or second complete remission; graft-versus-host disease (GVHD) prophylaxis contained either PTCy alone (n = 374) or ATG plus PTCy (n = 67), in addition to cyclosporine A (CsA) and mycophenolate mofetil (MMF) as other immunosuppressive agents. All transplantations were performed between 2011 and 2019. No major imbalances were observed between the 2 groups. For both groups, the median patient age was 56 years, and the median year of haplo-PBSCT was 2017. Most patients received a reduced-intensity conditioning regimen (57% in the PTCy group and 61% in the ATG+PTCy group; P = .54). The median follow-up was 19 months in the PTCy group versus 15 months in the ATG+PTCy group (P = .59), and the rate of neutrophil engraftment in the 2 groups was 97% and 98%, respectively. In univariate analysis, there were no statistical differences in transplantation outcomes between the 2 groups. In multivariate analysis, ATG+PTCy was associated with a lower risk of chronic GVHD compared with PTCy alone (hazard ratio, .46; 95% confidence interval, .23 to .93; P = .03). No between-group differences in the other transplantation outcomes were seen. In haplo-PBSCT, the addition of ATG to PTCy (with CsA and MMF) is feasible and better at preventing chronic GVHD and is associated with survival and transplantation outcomes comparable to those with PTCy alone, without increasing transplantation toxicity, mortality, or relapse incidence.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22024692
003      
CZ-PrNML
005      
20240528145838.0
007      
ta
008      
221017s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jtct.2022.06.006 $2 doi
035    __
$a (PubMed)35714906
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Battipaglia, Giorgia $u Hematology Department, Federico II University of Naples, Naples, Italy; Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy. Electronic address: giorgia.battipaglia@unina.it
245    10
$a Impact of the Addition of Antithymocyte Globulin to Post-Transplantation Cyclophosphamide in Haploidentical Transplantation with Peripheral Blood Compared to Post-Transplantation Cyclophosphamide Alone in Acute Myelogenous Leukemia: A Retrospective Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation / $c G. Battipaglia, M. Labopin, D. Blaise, JL. Diez-Martin, A. Bazarbachi, A. Vitek, P. Chevallier, L. Castagna, G. Grillo, E. Daguindau, J. López-Jiménez, Y. Koc, A. Ruggeri, A. Nagler, M. Mohty
520    9_
$a The use of haploidentical hematopoietic cell transplantation (haplo-HCT) with peripheral blood stem cells (PBSCs) to treat acute myelogenous leukemia (AML) is increasing. We explored whether the addition of antithymocyte globulin (ATG) to post-transplantation cyclophosphamide (PTCy) allows better outcomes compared with PTCy alone in haplo-HCT with PBSCs (haplo-PBSCT). We included 441 adult patients undergoing a first haplo-PBSCT for AML in first or second complete remission; graft-versus-host disease (GVHD) prophylaxis contained either PTCy alone (n = 374) or ATG plus PTCy (n = 67), in addition to cyclosporine A (CsA) and mycophenolate mofetil (MMF) as other immunosuppressive agents. All transplantations were performed between 2011 and 2019. No major imbalances were observed between the 2 groups. For both groups, the median patient age was 56 years, and the median year of haplo-PBSCT was 2017. Most patients received a reduced-intensity conditioning regimen (57% in the PTCy group and 61% in the ATG+PTCy group; P = .54). The median follow-up was 19 months in the PTCy group versus 15 months in the ATG+PTCy group (P = .59), and the rate of neutrophil engraftment in the 2 groups was 97% and 98%, respectively. In univariate analysis, there were no statistical differences in transplantation outcomes between the 2 groups. In multivariate analysis, ATG+PTCy was associated with a lower risk of chronic GVHD compared with PTCy alone (hazard ratio, .46; 95% confidence interval, .23 to .93; P = .03). No between-group differences in the other transplantation outcomes were seen. In haplo-PBSCT, the addition of ATG to PTCy (with CsA and MMF) is feasible and better at preventing chronic GVHD and is associated with survival and transplantation outcomes comparable to those with PTCy alone, without increasing transplantation toxicity, mortality, or relapse incidence.
650    _2
$a antilymfocytární sérum $7 D000961
650    _2
$a kostní dřeň $7 D001853
650    _2
$a cyklofosfamid $7 D003520
650    _2
$a cyklosporin $7 D016572
650    12
$a nemoc štěpu proti hostiteli $7 D006086
650    _2
$a lidé $7 D006801
650    12
$a akutní myeloidní leukemie $7 D015470
650    _2
$a lidé středního věku $7 D008875
650    _2
$a kyselina mykofenolová $7 D009173
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a haploidentická transplantace $7 D000075442
655    _2
$a časopisecké články $7 D016428
700    1_
$a Labopin, Myriam $u European Society for Blood and Marrow Transplantation study office, Paris, France; Hematology Department, Transplantation and Cellular Therapy Service, Hôpital Saint Antoine, Paris, France; St Antoine Research Center, INSERM Sorbonne University CRSA, Hopital St Antoine, Paris, France
700    1_
$a Blaise, Didier $u Transplantation and Cellular Therapy Program, Institut Paoli-Calmettes, CNRS, INSERM, CRCM, Aix Marseille Universitaire, Marseille, France
700    1_
$a Diez-Martin, Jose Luis $u Haematology and Haemotherapy Department, Hospital General Universitario Gregorio Marañón, Departamento de Medicina, Instituto de Investigación Sanitaria Gregorio Marañon, UCM, Madrid, Spain
700    1_
$a Bazarbachi, Ali $u Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
700    1_
$a Vitek, Antonin $u Hematology Service, Institute of Hematology and Blood Transfusion, Prague, Czech Republic
700    1_
$a Chevallier, Patrice $u Department of Hematology, Centre Hospitalier Universitaire de Nantes, Nantes, France
700    1_
$a Castagna, Luca $u Humanitas Clinical and Research Center, IRCCS, Milan, Italy
700    1_
$a Grillo, Giovanni $u Hematology Department, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
700    1_
$a Daguindau, Etienne $u Hematology Department, Centre Hospitalier Regional Universitaire Besançon, INSERM, UMR 1098, Université de Franche-Comté, Besançon, France
700    1_
$a López-Jiménez, Javier $u Hospital Ramón y Cajal, Madrid, Spain
700    1_
$a Koc, Yener $u Medicana International, Istanbul, Turkey
700    1_
$a Ruggeri, Annalisa $u Haematology and BMT, IRCCS Ospedale San Raffaele, Milan, Italy
700    1_
$a Nagler, Arnon $u Department of Clinical Medicine and Surgery, Federico II University of Naples, Naples, Italy; Chaim Sheba Medical Center, Tel-Hashomer, Israel
700    1_
$a Mohty, Mohamad $u European Society for Blood and Marrow Transplantation study office, Paris, France; Hematology Department, Transplantation and Cellular Therapy Service, Hôpital Saint Antoine, Paris, France; St Antoine Research Center, INSERM Sorbonne University CRSA, Hopital St Antoine, Paris, France $7 xx0317729
773    0_
$w MED00208298 $t Transplantation and cellular therapy $x 2666-6367 $g Roč. 28, č. 9 (2022), s. 587.e1-587.e7
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35714906 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20221017 $b ABA008
991    __
$a 20240528145835 $b ABA008
999    __
$a ok $b bmc $g 1854432 $s 1175982
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 28 $c 9 $d 587.e1-587.e7 $e 20220614 $i 2666-6367 $m Transplantation and cellular therapy $n Transplant Cell Ther $x MED00208298
LZP    __
$a Pubmed-20221017

Najít záznam

Citační ukazatele

Možnosti archivace